-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cancer is closely related to genetic mutations
In a new study published recently in the journal Nature Cancer, researchers found that an antibiotic discovered in the 1950s, novobiocin (NVB), can effectively kill DNA carrying homologous recombination (HR) Repair defective tumor cells
In a study published as early as 2015, a research team led by Dr.
In this study, researchers conducted high-throughput small molecule screening for BRCA-deficient tumors to find compounds that can affect tumor growth
The study of novobiocin binding target found that it can bind to the ATPase domain of POLθ and inhibit its activity, achieving the same inhibitory effect as knocking out POLθ enzyme
"PARP inhibitors have made important progress in the treatment of cancers that carry BRCA1, BRCA2 or other genetic defects related to DNA repair
The researchers plan to initiate clinical trials to test the efficacy of novobiocin in BRCA-deficient cancer patients who are resistant to PARP inhibitors
Reference materials:
[1] Zhou, J.
[2] Antibiotic Novobiocin found to kill tumor cells with DNA-repair glitch.
